NASDAQ:CELC Celcuity (CELC) Stock Price, News & Analysis $18.73 -0.42 (-2.19%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$18.60▼$19.7750-Day Range$14.10▼$19.1552-Week Range$8.39▼$22.19Volume376,192 shsAverage Volume269,773 shsMarket Capitalization$657.42 millionP/E RatioN/ADividend YieldN/APrice Target$29.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Celcuity alerts: Email Address Celcuity MarketRank™ Stock AnalysisAnalyst RatingBuy3.17 Rating ScoreUpside/Downside55.9% Upside$29.20 Price TargetShort InterestBearish6.47% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.71Based on 16 Articles This WeekInsider TradingSelling Shares$5,488 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.86) to ($3.83) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.28 out of 5 starsMedical Sector349th out of 936 stocksMedical Laboratories Industry9th out of 18 stocks 4.6 Analyst's Opinion Consensus RatingCelcuity has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCelcuity has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Celcuity's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.47% of the outstanding shares of Celcuity have been sold short.Short Interest Ratio / Days to CoverCelcuity has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Celcuity has recently increased by 5.58%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCelcuity does not currently pay a dividend.Dividend GrowthCelcuity does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CELC. Previous Next 2.6 News and Social Media Coverage News SentimentCelcuity has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Celcuity this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for CELC on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added Celcuity to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Celcuity insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,488.00 in company stock.Percentage Held by Insiders24.29% of the stock of Celcuity is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.33% of the stock of Celcuity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Celcuity's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Celcuity are expected to decrease in the coming year, from ($2.86) to ($3.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Celcuity is -6.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Celcuity is -6.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCelcuity has a P/B Ratio of 3.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Celcuity's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Awesomely, LLCAutomatic Income (from home)Everyone’s talking about this new income hack that could generate triple digit returns on your money. But here’s the best part…Watch this short video About Celcuity Stock (NASDAQ:CELC)Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.Read More CELC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CELC Stock News HeadlinesJuly 25 at 8:32 AM | americanbankingnews.comQ2 2024 Earnings Estimate for Celcuity Inc. Issued By Leerink Partnrs (NASDAQ:CELC)July 23 at 6:39 PM | msn.comLeerink Partners Initiates Coverage of Celcuity (CELC) with Outperform RecommendationJuly 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.July 23 at 8:34 AM | americanbankingnews.comCelcuity Inc. (NASDAQ:CELC) Receives Average Recommendation of "Buy" from BrokeragesJuly 23 at 6:56 AM | americanbankingnews.comCelcuity (NASDAQ:CELC) Lifted to Strong-Buy at Leerink PartnrsJuly 23 at 5:23 AM | americanbankingnews.comCelcuity (NASDAQ:CELC) Receives New Coverage from Analysts at SVB LeerinkJuly 5, 2024 | seekingalpha.comCelcuity: Flying A Phase 3 Trial Right Under Your NoseJune 3, 2024 | globenewswire.comCelcuity To Participate in Jefferies Global Healthcare ConferenceJuly 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.May 30, 2024 | globenewswire.comCelcuity Announces Pricing of Underwritten Common Stock OfferingMay 30, 2024 | globenewswire.comCelcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt FinancingMay 16, 2024 | markets.businessinsider.comGrowth Potential Drives Buy Rating for Celcuity Despite Current LossesMay 16, 2024 | markets.businessinsider.comCelcuity’s Clinical and Financial Momentum Justifies Buy Rating and $24 Price TargetMay 16, 2024 | msn.comCelcuity Inc. (NASDAQ:CELC) Q1 2024 Earnings Call TranscriptMay 16, 2024 | finance.yahoo.comCelcuity Inc (CELC) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges and ...May 15, 2024 | msn.comCelcuity Non-GAAP EPS of -$0.59May 15, 2024 | globenewswire.comCelcuity Inc. Reports First Quarter Financial Results and Provides Corporate UpdateMay 8, 2024 | globenewswire.comCelcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference CallSee More Headlines Receive CELC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celcuity and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:CELC CUSIPN/A CIK1603454 Webwww.celcuity.com Phone(763) 392-0767FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$29.20 High Stock Price Target$40.00 Low Stock Price Target$23.00 Potential Upside/Downside+55.9%Consensus RatingBuy Rating Score (0-4)3.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,780,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-61.66% Return on Assets-43.51% Debt Debt-to-Equity Ratio0.28 Current Ratio11.23 Quick Ratio11.23 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.48 per share Price / Book3.42Miscellaneous Outstanding Shares35,100,000Free Float26,575,000Market Cap$657.42 million OptionableOptionable Beta0.81 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Brian F. Sullivan (Age 62)Co-Founder, Chairman & CEO Comp: $478.12kDr. Lance G. Laing Ph.D. (Age 62)Co-Founder, Chief Science Officer, VP, Secretary & Director Comp: $389.55kMs. Vicky Hahne (Age 58)Chief Financial Officer Comp: $281.59kDr. John R. MacDonald Dabt (Age 69)Ph., Ph.D., Senior Vice President of R&D Ms. Sheri SmithActing Head of Clinical OperationsMr. Igor Gorbatchevsky M.D.Chief Medical OfficerMr. Eldon C. Mayer III (Age 63)M.B.A., Chief Commercial Officer More ExecutivesKey CompetitorsExagenNASDAQ:XGNRenalytixNASDAQ:RNLXFortreaNASDAQ:FTRENational HealthCareNYSE:NHCTeladoc HealthNYSE:TDOCView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 19,811 shares on 7/26/2024Ownership: 0.189%Hennion & Walsh Asset Management Inc.Bought 54,217 shares on 7/20/2024Ownership: 0.154%Wealth Enhancement Advisory Services LLCBought 1,600 shares on 7/16/2024Ownership: 0.063%Richard E BullerSold 350 sharesTotal: $5,488.00 ($15.68/share)California State Teachers Retirement SystemSold 1,035 shares on 5/16/2024Ownership: 0.006%View All Insider TransactionsView All Institutional Transactions CELC Stock Analysis - Frequently Asked Questions How have CELC shares performed this year? Celcuity's stock was trading at $14.57 at the beginning of 2024. Since then, CELC stock has increased by 28.6% and is now trading at $18.73. View the best growth stocks for 2024 here. How were Celcuity's earnings last quarter? Celcuity Inc. (NASDAQ:CELC) issued its quarterly earnings data on Wednesday, May, 15th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.07. When did Celcuity IPO? Celcuity (CELC) raised $18 million in an IPO on Wednesday, September 20th 2017. The company issued 2,000,000 shares at $8.00-$10.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO. Who are Celcuity's major shareholders? Top institutional shareholders of Celcuity include Bank of New York Mellon Corp (0.19%), Hennion & Walsh Asset Management Inc. (0.15%) and Wealth Enhancement Advisory Services LLC (0.06%). Insiders that own company stock include David Dalvey, Richard Nigon and Richard E Buller. View institutional ownership trends. How do I buy shares of Celcuity? Shares of CELC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Celcuity own? Based on aggregate information from My MarketBeat watchlists, some other companies that Celcuity investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Evoke Pharma (EVOK), Amicus Therapeutics (FOLD), Allena Pharmaceuticals (ALNA) and This page (NASDAQ:CELC) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celcuity Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celcuity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
